Search
carbonic anhydrase inhibitor
Carbonic anhydrase inhibitors were developed from testing of sulfonamides for ability to inhibit carbonic anhydrase after it was found that sulfanilamide inhibited carbonic anhydrase.
Monitor:
- serum electrolytes every 6 months
- complete blood count (CBC) every 6 months
Adverse effects:
- Stevens-Johnson syndrome & toxic epidermal necrolysis [4]
- aplastic anemia [4]
Notes:
- inhibition of mitochondrial carbonic anhydrase suggested to have benefit for aging & neurodegenerative disease [2]
Interactions
drug interactions
drug adverse effects (more general classes)
monitor with carbonic anhydrase inhibitors
Related
sulfonamide
Specific
acetazolamide (Diamox)
brinzolamide (Azopt)
dichlorphenamide (Daranide)
dorzolamide (Trusopt)
methazolamide (Neptazane)
sulfanilamide
sulthiame; trolone; sulphenyltame; sulthiamine; (Ospolot)
topiramate (Topamax, Qudexy XR, Trokendi XR)
General
diuretic
enzyme inhibitor
References
- The Pharmacological Basis of Therapeutics, 9th ed.
Gilman et al, eds. Permagon Press/McGraw Hill, 1996 pg 691
- University of Nottingham. Oct 10, 2016
Cell protein offers new hope in fighting the effects of aging.
https://www.nottingham.ac.uk/news/pressreleases/2016/october/cell-protein-offers-new-hope-in-fighting-the-effects-of-aging.aspx
- Yang MS, Lee JY, Kim J et al
Searching for the culprit drugs for Stevens-Johnson syndrome and
toxic epidermal necrolysis from a nationwide claim database in Korea.
J Allergy Clin Immunol Pract 2020 Feb; 8:690
PMID: 31614216
https://www.sciencedirect.com/science/article/abs/pii/S221321981930858X
- Popovic MM, Schlenker MB, Thiruchelvam D et al
Serious Adverse Events of Oral and Topical Carbonic Anhydrase Inhibitors.
JAMA Ophthalmol. 2022;140(3):235-242
PMID: 35084437 PMCID: PMC8796060 (available on 2023-01-27)
https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2788394